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Abstract
Background: The Ebola virus is transmitted by direct contact with bodily fluids of infected individuals, eliciting death rates
as high as 90% among infected humans. Currently, replication defective adenovirus-based Ebola vaccine is being studied in
a phase I clinical trial. Another Ebola vaccine, based on an attenuated vesicular stomatitis virus has shown efficacy in post-
exposure treatment of nonhuman primates to Ebola infection. In this report, we modified the common recombinant
adenovirus serotype 5-based Ebola vaccine expressing the wild-type ZEBOV glycoprotein sequence from a CMV promoter
(Ad-CMVZGP). The immune response elicited by this improved expression cassette vector (Ad-CAGoptZGP) and its ability to
afford protection against lethal ZEBOV challenge in mice was compared to the standard Ad-CMVZGP vector.
Methodology/Principal Findings: Ad-CMVZGP was previously shown to protect mice, guinea pigs and nonhuman primates
from an otherwise lethal challenge of Zaire ebolavirus. The antigenic expression cassette of this vector was improved
through codon optimization, inclusion of a consensus Kozak sequence and reconfiguration of a CAG promoter (Ad-
CAGoptZGP). Expression of GP from Ad-CAGoptZGP was substantially higher than from Ad-CMVZGP. Ad-CAGoptZGP
significantly improved T and B cell responses at doses 10 to 100-fold lower than that needed with Ad-CMVZGP. Additionally,
Ad-CAGoptZGP afforded full protections in mice against lethal challenge at a dose 100 times lower than the dose required
for Ad-CMVZGP. Finally, Ad-CAGoptZGP induced full protection to mice when given 30 minutes post-challenge.
Conclusions/Significance: We describe an improved adenovirus-based Ebola vaccine capable of affording post-exposure
protection against lethal challenge in mice. The molecular modifications of the new improved vaccine also translated in the
induction of significantly enhanced immune responses and complete protection at a dose 100 times lower than with the
previous generation adenovirus-based Ebola vaccine. Understanding and improving the molecular components of
adenovirus-based vaccines can produce potent, optimized product, useful for vaccination and post-exposure therapy.
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Introduction
Ebola virus (EBOV) is a member of the Filoviridae family causing
a viral hemorrhagic fever with a lethality that can reach beyond
90% [1,2]. While the precise mode of natural viral transmission to
humans and nonhuman primates remains elusive, there are
indications that bats may act as a primary source of infection [3].
EBOV causes hemorrhagic fever following virus entry in
susceptible organisms where the virus appears to initially infect
monocytes, macrophages, and dendritic cells leading to deregu-
lated activation of innate immunity and a systemic inflammatory
response syndrome. This results in massive destruction of critical
organs, vascular damage and haemorrhage within 5–7 days post-
exposure [4,5]. Outbreaks of EBOV have primarily been localized
to Central Africa with relatively low impact on human health
worldwide, despite inflicting devastating consequences on affected
communities. EBOV has however drawn increasing interest in the
past years due to an increased number of natural human outbreaks
and its potential use in biological warfare [6].
Human adenovirus serotype 5 (Ad) was initially developed as a
delivery vehicle for therapeutic transgenes in a wide variety of
animal models of genetic disease [7]. However, an inherent
characteristic of recombinant Ad for gene therapy applications is
the ability of the virus to elicit a strong immune response even in
immunocompetent hosts, making Ad-based vectors attractive
vaccine carriers [8]. Vaccination with Ad expressing the Zaire
ebolavirus (ZEBOV) envelope glycoprotein (Ad-ZGP) has been
shown to protect mice, guinea pigs and nonhuman primates from
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5308lethal ZEBOV challenges [9–11]. It is also currently being studied
in a phase I clinical trial recently initiated in normal adults with
the objective of evaluating safety and immune responses to the
vaccine (http://clinicaltrials.gov/show/NCT00374309).
The use of attenuated vesicular stomatitis virus (VSV) vaccine
platforms expressing the Ebola virus surface glycoprotein has also
been useful for the treatment and protection of three animal
models post-exposure [1,12]. Administration of the VSV-based
vaccine as late as 24 hours after lethal Ebola virus infection,
resulted in 50% and 100% survival, in guinea pigs and mice
respectively while 50% of rhesus macaques tested were protected
when treated 20 to 30 minutes after exposure to Ebola [12]. While
VSV appears to be one effective treatment strategy for Ebola
infections, adenovirus-based vaccine may offer further useful
characteristics such as the rapidity to produce large amounts of
transgene which can promote a robust immune response soon
after vaccination [1].
Viral regulatory elements such as the human cytomegalovirus
immediate early gene (CMV) promoter induce high-level consti-
tutive expression in vitro in a variety of mammalian cell lines and
thus were largely used to generate many of the early gene transfer
vectors [13]. Other technologies were developed in order to
enhance gene expression notably for DNA vaccine platforms. In
this context, codon optimization for translation in mammalian
cells along with the hybrid CAG promoter which combines the
human cytomegalovirus immediate early gene enhancer and a
modified chicken beta-actin promoter were shown to improve
protective immune responses after vaccination [14,15]. Targeting
of dendritic cells and high expression profiles are two major
characteristics making recombinant adenovirus such a robust
vaccine vector.
In this report, we modified the common recombinant
adenovirus serotype 5-based Ebola vaccine expressing the wild-
type ZEBOV glycoprotein sequence from a CMV promoter (Ad-
CMVZGP) to enhance expression of the envelope antigen. The
immune response elicited by this improved expression cassette
vector (Ad-CAGoptZGP) and its ability to afford protection
against lethal ZEBOV challenge in mice was compared on a dose-
to-dose basis to that of the standard Ad-CMVZGP vector.
Results
Increased Ebola GP expression from an improved
expression cassette adenovirus vector
The antigenic expression cassette of an E1/E3 deleted
adenovirus serotype 5 vector was improved to provide enhanced
expression of the Ebola GP. Improvements included codon
optimization for translation in mammalian cells, inclusion of a
consensus Kozak sequence and identification of a more efficient
configuration of a CAG promoter. Portions of the 59 untranslated
region (UTR) of pCAGGS-MCS downstream of the CAG
promoter were progressively truncated using endogenous restric-
tion enzyme sites within the UTR sequence. The initial objective
of systematically deleting portions of the 59 UTR was to identify
the minimal promoter region, capable of accommodating larger
inserts for different applications. The CAGD829 deletion of the 59
UTR resulted in a statistically significant substantial increase
(p,0.001) in expression of an enhanced green fluorescent protein
(EGFP) reporter gene compared to the full promoter containing
EGFP (pCAGGS-EGFP) in transfected HEK 293T cells as
determined by flow activated cell sorting (FACS) (Figure 1). The
plasmid pCAGD829-EGFP repeatedly showed the highest inten-
sity of EGFP and the regulatory element from the enhancer to the
multiple cloning sites (MCS; named CAGa) was selected to drive
the expression of the codon optimized Ebola GP in the adenovirus
vector. The codon optimized ZGP was inserted downstream of the
CAGa promoter in the adenovirus vector and Ebola GP
expression was evaluated by western blot analysis following
infection of HEK 293 cells at a multiplicity of infection (M.O.I.)
of 5. An adenovirus encoding a CMV driven wild-type Ebola GP
(Ad-CMVZGP) was used in parallel at the same M.O.I. for
comparative analysis. Cell free extracts were recovered at 24, 48
and 72 hours post-infection and each separated by SDS-PAGE
electrophoresis. Western blot analysis using a ZGP monoclonal
antibody showed a single band corresponding to the predicted
molecular weight of glycosylated ZGP at substantially higher levels
in cell lysates infected with the Ad-CAGoptZGP than with the Ad-
CMVZGP vector at each time point (Figure 2). Densitometry
evaluation of the bands corresponding to ZGP revealed an average
band density of 2.8 from the Ad-CMVZGP and of 18.0 from the
Ad-CAGoptZGP vector at 48 hours post-infection. A marked
increase of 3 to 7-fold was observed between 24 and 72 hours post-
infection in samples infected with the Ad-CAGoptZGP vector
when compared to Ad-CMVZGP. Similar ratios were observed
from infected Vero E6 or MDCK cells with Ad-CAGoptZGP
consistently expressing higher levels of ZGP than Ad-CMVZGP
(data not shown).
Enhanced T and B cell immune responses with low dose
of Ad-CAGoptZGP
Stimulation of CD8+ T cells expressing IFN-c was monitored
following vaccination with Ad-CMVZGP or Ad-CAGoptZGP in
mice. B10.BR mice were vaccinated I.M. with either Ad-
CMVZGP at a concentration of 1610
5,1 610
6 or 1610
7
infectious forming units (IFU)/mouse or Ad-CAGoptZGP at a
concentration of 1610
4,1 610
5 or 1610
6 IFU/mouse. The Ad-
CAGoptZGP was administered over a lower spectrum of doses
because of the higher expression profile of the ZGP antigen. The
mice were sacrificed eight days post-immunization and the
percentage of interferon-c (IFN-c)-CD8+ T cells was determined
by FACS. Ad-CAGoptZGP at a dose of 1610
5 IFU/mouse
elicited a frequency of 1.360.3% positive IFN-c producing CD8+
T cells compared to 0.360.16% induced by Ad-CMVZGP at the
same dose (Figure 3A). The frequency of positive IFN-c producing
CD8+ T cells increased to 2.260.7% for Ad-CAGoptZGP at
1610
6 IFU/mouse compared to 1.160.4% with the same dose of
Ad-CMVZGP (Figure 3A). The frequency of IFN-c+CD8 T cells
with Ad-CMVZGP at 1610
7 IFU/mouse was at 1.660.4% in
average (Figure 3A). Overall, the average frequency of positive
IFN-c producing CD8+ T cells was higher with 1610
6 IFU/
mouse of Ad-CAGoptZGP than with 1610
7 IFU/mouse of Ad-
CMVZGP although with a low statistical significance (p=0.0454).
Neutralizing antibody was used to evaluate the B cell response
in the serum of vaccinated animals. Sera from B10.BR mice were
collected 25 days after immunization and assayed for the presence
of neutralizing antibodies against ZEBOV expressing the en-
hanced green fluorescent protein reporter gene (ZEBOV-EGFP)
[16]. Neutralizing antibodies were detected in sera obtained from
Ad-CAGoptZGP immunized mice at all vaccine doses of 1610
4,
1610
5 and 1610
6 IFU/mouse with reciprocal dilutions ranging
from 40610 to 200620 (Figure 3B). Mice immunized with Ad-
CMVZGP had an average neutralizing antibody level of 50620
reciprocal dilutions starting at the dose of 1610
7 IFU/mouse.
Mice administered Ad-CAGoptZGP at 1610
4 IFU/mouse
demonstrated neutralizing antibody levels similar to levels
obtained from mice vaccinated with Ad-CMVZGP at 1610
7
IFU/mouse (p=0.1).
Ad-Based Ebola Vaccine
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at low doses against mouse-adapted ZEBOV
To determine the protective efficacy of Ad-CMVZGP versus
Ad-CAGoptZGP vaccine vector, groups of 10 B10.BR mice were
immunized with different doses of adenovirus vector and
challenged 28 days later with a lethal dose (LD50=1000) of
mouse-adapted ZEBOV [17]. All control mice vaccinated with
phosphate buffered saline (PBS) died by day 9 post-challenge
whereas all mice vaccinated with doses of 1610
4,1 610
5 and
1610
6 IFU/mouse of Ad-CAGoptZGP were fully protected with
no weight loss or other clinical signs of disease (Table 1).
Protection was complete in mice vaccinated with Ad-CMVZGP
at 1610
6 and 1610
7 IFU/mouse but was only partially protective
at 1610
5 IFU/mouse (Table 1). Mice vaccinated with the lower
dose of 1610
5 IFU/mouse had 60% mortality and up to 17%
weight loss in surviving animals (Table 1).
Infected mice survive a lethal challenge with mouse-
adapted ZEBOV when vaccinated soon after exposure
The substantial improvement in protection and enhanced
immune responses observed with low dose of the Ad-CAGoptZGP
vaccine raised the question whether this vaccine vector could
afford post-exposure protection against ZEBOV in mice. To
answer this question, B10.BR mice were challenged with
10006LD50 of mouse-adapted ZEBOV and vaccinated I.M.
30 minutes later with either Ad-CAGoptZGP or Ad-CMVZGP at
a concentration of 5610
7 IFU/mouse. The challenge was
uniformly lethal in PBS control mice and 22% of mice treated
with Ad-CMVZGP survived although weight loss was observed
(Figure 4A and B). In contrast, 100% of the mice administered Ad-
CAGoptZGP survived the challenge however weight loss of up to
14% was also observed (Figure 4A and B).
One of the possible mechanisms contributing to post-exposure
protection is the induction of an immune response reaching
protective levels before Ebola virus can kill the host. Immune
responses were monitored at day 6 after vaccination with each
vector to assess the levels of activated T cells and neutralizing
antibody detectable just before mice are expected to succumb to a
mouse-adapted Ebola challenge of 10006LD50 (between 7 to 10
days post-challenge). Stimulation of CD8+ T cells expressing IFN-
c, TNF-a and/or IL-2 following Ad-CMVZGP or Ad-CA-
GoptZGP was evaluated after I.M. vaccination with 1610
8
IFU/mouse. Immunized mice were sacrificed 6 days post-
immunization and the percentage of IFN-c, TNF-a and/or IL-2
CD8+ T cells were determined by FACS. Ad-CAGoptZGP
vaccinated mice had a frequency of 5.260.604%, 4.260.379% or
1.260.121% positive IFN-c, TNF-a or IL-2 producing CD8+ T
cells respectively. In comparison, Ad-CMVZGP had a frequency
of 360.521%, 1.960.340% or 0.2560.118% positive IFN-c,
TNF-a or IL-2 producing CD8+ T cells respectively (Figure 5).
Triple positive CD8+ T cells expressing IFN-c, TNF-a and IL-2
were detected in 0.8560.154% of the total from Ad-CAGoptZGP
vaccinated mice compared to 0.260.055% in total CD8+ T cells
Figure 1. Expression intensity of EGFP reporter gene in transfected HEK 293T cells as determined by FACS. Portions of the 59
untranslated region of pCAGGS downstream of the CAG promoter were systematically removed generating pCAGGSD764-EGFP, pCAGGSD829-EGFP
and pCAGGSD947-EGFP. Assays were preformed in triplicate and repeated twice, the data shown is from one experiment. Error bars represent the
standard deviation of the data. * p,0.001.
doi:10.1371/journal.pone.0005308.g001
Figure 2. Western blot expression analysis of Ad-CMVZGP or
Ad-CAGoptZGP. Proteins isolated from infected HEK 293 cells were
separated by a 10% SDS PAGE then transferred to PVDF membrane. A
mouse monoclonal anti-ZGP was used as the primary antibody and a
goat anti-mouse horseradish peroxidase (HRP) conjugated antibody as
the secondary antibody. 24, 48 and 72 hours indicate the time of total
protein harvest post-infection. Band density corresponding to each lane
is shown as determined by densitometry of the bands. The control
represents untreated HEK 293 cells. An M.O.I. of 5 was used to infect the
cells with either Ad-CMVZGP or Ad-CAGoptZGP for each time point. The
preparation of Ad-CAGoptZGP or Ad-CMVZGP used had a non-
infectious to infectious ratio of 73:1or 19:1 respectively.
doi:10.1371/journal.pone.0005308.g002
Ad-Based Ebola Vaccine
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5,1 610
6 and 1610
7 IFU/
mouse) or Ad-CAGoptZGP (1610
4,1 610
5 and 1610
6 IFU/mouse) and splenocytes were harvested 8 days later for A. IFN-c CD8+ T cells frequency
analysis or B. Neutralizing antibody (NAB) titers. Four to five mice were analyzed per group and the experiment was repeated twice. Levels of NAB to
ZEBOV-EGFP were evaluated 25 days post-vaccination. Error bars represent the standard deviation of the data. n.d. refers to assays that were not
done for Ad-CAGoptZGP at that IFU/mouse. * p=0.0454; ** p=0.1.
doi:10.1371/journal.pone.0005308.g003
Table 1. Survival and weight loss of mice challenged with ZEBOV 28 days post-vaccination.
Vaccine Concentration (IFU/Mouse) Survival (Percentage) Weight Loss (Percentage)
Ad-CMVZGP 1610
7 100 0
Ad-CMVZGP 1610
6 100 0
Ad-CMVZGP 1610
5 40 17
Ad-CAGoptZGP 1610
6 100 0
Ad-CAGoptZGP 1610
5 100 0
Ad-CAGoptZGP 1610
4 100 0
Control na
1 0 .25
Eight to nine B10.BR mice were used in each group.
1not applicable.
doi:10.1371/journal.pone.0005308.t001
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frequencies of IFN-c, TNF-a or IL-2 producing CD8+ T cells
individually or combined (triple positive) were increased with
statistical significance from mice immunized with Ad-CA-
GoptZGP compared to Ad-CMVZGP (p,0.001, p,0.001,
p,0.01, p,0.01 respectively). Neutralizing antibody assay
performed on B10.BR mice sera collected 6 days after immuni-
zation revealed levels of 16+/29 reciprocal dilution following
vaccination with Ad-CAGoptZGP whereas no neutralizing
antibodies were detected in sera of Ad-CMVZGP immunized
mice (data not shown).
Discussion
Vaccine vectors derived from adenoviruses have been shown to
be efficacious in a number of animal species showing susceptibility
to different infectious agents [18,19]. However, acute toxicity has
also been reported with the administration of high doses of this
virus [20]. The present study systematically analyzed the effect of
increasing antigenic expression from an adenovirus-based vaccine
on immune responses and protective efficacy in mice against
mouse-adapted ZEBOV. Technologies mainly evaluated and
adopted by the DNA vaccine community including gene
optimization was used to develop the described vector for use
against ZEBOV. The improved Ad-CAGoptZGP vaccine vector
was evaluated side-by-side with the commonly used CMV driven
wild-type Ebola GP-encoding adenovirus which has shown
protective efficacy in nonhuman primates against ZEBOV [21].
The human cytomegalovirus immediate early gene (CMV)
promoter induces high-level constitutive expression of encoded
genes in vitro and in vivo in a variety of cell types [13,22,23] and
therefore has been incorporated into many recombinant adeno-
virus-based vaccines. The present study indicates that an
optimized antigenic expression cassette including the modified
CAG promoter and codon optimization can substantially improve
immune responses and protection generated by an adenovirus-
based vaccine. The optimized Ad-CAGoptZGP vaccine strength-
ened immune responses at a doses 10 to 100-fold lower than those
commonly used for the Ad-CMV driven Ebola GP vaccine. The
optimized vaccine also fully protected mice against a lethal
challenge with mouse-adapted ZEBOV at a dose 100 times lower
than the minimal dose required to achieve full protection with the
first generation adenovirus vaccine. Understanding the relative
contribution of each molecular determinant (i.e. promoter, Kozak
sequence, codon optimization etc.) individually may help design
future optimized adenovirus-based as well as other sub-unit
vaccines. These experiments are currently underway.
Overall, the substantial improvement in vaccine efficacy can be
useful for many applications. The same protective efficacy can be
achieved with lower doses of adenovirus vector allowing for a
more extended use of each preparation and importantly
minimizing toxicity from the vaccine vector. Alternatively,
protection can be achieved with doses equivalent or even lower
than for example the lowest dose of 1610
9 virus particles currently
evaluated in clinical trials [http://www.clinicaltrials.gov/ct/
show/NCT00374309?order=1].
Figure 4. Protective efficacy following intramuscular (I.M.) immunization 30 minutes post-challenge. Groups of nine to eleven B10.BR
mice were challenged with 10006LD50 of mouse-adapted ZEBOV and vaccinated I.M. 30 minutes later with a single dose of 5610
7 IFU of Ad-
CAGoptZGP or Ad-CMVZGP per mouse. Preparations of Ad-CAGoptZGP or Ad-CMVZGP had non-infectious to infectious ratio of 73:1 or 19:1
respectively. Error bars represent the standard deviation of the data. Data represent A. percent survival and B. percent body weight loss over time.
Control mice were PBS-treated 30 minutes after challenge. This experiment was repeated once with B10.BR mice and once with BALB/c mice and
generated similar results.
doi:10.1371/journal.pone.0005308.g004
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mice infected with mouse-adapted ZEBOV was observed following
administration of a relatively low dose (5610
7 IFU/mouse) of the
improved vaccine 30 minutes after challenge, supporting the
concept of post-exposure induced protection. Although, the precise
mechanism remains to be fully elucidated, a higher number of IFN-
c,T N F - a and IL-2 positive CD8 T cells were detected from
splenocytes of Ad-CAGoptZGP immunized mice 6 days post-
vaccination when compared to Ad-CMVZGP immunized mice.
Levels of NAB were also detected at day 6, but only from mice
vaccinated with the improved Ad-CAGoptZGP vector. This
suggests that in addition to the T cell response, B cells may also
play a role in increasing survivability in mice. However, antibodies
alone may not be sufficient as a small percentage of mice vaccinated
with Ad-CMVZGP survived despite the lack of detectable NAB.
These observations would be in agreement with the concept that the
improved adenovirus vaccine could stimulate a more rapid immune
response which reaches protective levels before ZEBOV could cause
irreversible damage to the host. Although similar post-exposure
protection against different filoviruses has been reported using the
VSV vaccine platform [12,24] extending this important character-
istic of post-exposure efficacy from a replication competent filovirus
vaccine to a replication defective vaccine vector such as those
currently being evaluated in several clinical trials and newer
optimized versions such as these should be valuable. Overall, these
results support further evaluation of the improved Ad-CAGoptZGP
vaccine in other animal models of ZEBOV infection such as guinea
pigs and nonhuman primates.
Materials and Methods
Construction of the optimized expression cassette
A minimal CAG (chicken-b-actin promoter and cytomegalovi-
rus enhancer) sequence was identified from plasmid pCAGGS-
MCS following the sequential deletion of the 59 non-translated
region in pCAGGS-EGFP expressing the enhanced green
fluorescent protein (EGFP). Three truncated versions of
pCAGGS-EGFP were generated using the restriction enzymes
PspOMI/XbaI( D764 base pairs), Eco47III/XbaI( D829 base pairs)
or Eco47111/Acc65I (D947 base pairs) that cut within the UTR
sequence. The digested DNA was filled in with Klenow fragments
(NEB Inc., Ipswich, MA) then ligated with T4 DNA ligase
generating pCAGGSD764-EGFP, pCAGGSD829-EGFP and
pCAGGSD947-EGFP or pCAGb, pCAGa, and pCAGc, respec-
tively. Transfection of wild-type pCAGGS-EGFP, pCAGa,
pCAGb or pCAGc into human embryonic kidney cell line
(HEK 293T) was performed with the lipid-based Effectene
transfection system according to the manufacturer recommenda-
tions (Qiagen, Mississauga, Ontario).
Gene synthesis of human codon-optimized Ebola GP
The ZEBOV GP sequence (Genbank/NCBI; Mayinga strain
76 accession number AF086833 protein accession number
Q05320) used contains an additional adenosine in the editing site
for the production of full length GP which is subject to post-
translational modifications (cleavage, glycosylation; N-linked and
O-linked carbohydrates) [25]. The GP sequence was codon-
optimized for translation in mammalian cells generating optZGP
for increased antigenic expression from the adenovirus-based
vaccine. Based on NCBI human codon usage databases, the wild-
type ZEBOV GP sequence uses 36% of codons most frequently
found in mammalian cells. OptZGP was further codon optimized
to 70% by choosing the most abundant and/or second most
abundant codons. The optZGP was synthesized from 40-mer
oligonucleotides and then inserted into the pCAGa expression
vector. Briefly, 121 oligonucleotide primers (Operon Biotechnol-
ogies, Inc., Huntsville, Alabama) each 40 nucleotides in length
with an overlap of 20 nucleotides were generated to encode the full
length codon-optimized optZGP open reading frame (ORF). The
oligonucleotides were then combined in a three cycle PCR
protocol to produce a complete double stranded optZGP using a
method previously described [26]. A consensus Kozak sequence
was also introduced into the forward primer of the optZGP to
facilitate optZGP expression. The final amplification of the codon-
optimized optZGP was accomplished by PCR using iProof High
Fidelity Polymerase (BioRad) and the construct was confirmed by
sequencing. The full length opt ZGP was then cloned downstream
of pCAGa.
Figure 5. T cell frequency analysis at day 6 post-immunization. Groups of 4 B10.BR mice were vaccinated I.M. with 1610
8 IFU/mouse of Ad-
CMVZGP or Ad-CAGoptZGP and splenocytes were harvested 6 days later, re-stimulated with the peptide TELRTFSI, and production of IFN-c, TNF-a,
and Il-2 from CD8+ T cells was monitored by FACS. Error bars represent the standard deviation of the data. The experiment was repeated once and
showed similar results. * p,0.001; ** p,0.001; *** p,0.01; **** p,0.01.
doi:10.1371/journal.pone.0005308.g005
Ad-Based Ebola Vaccine
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The molecular clone of E1/E3-deleted adenovirus vector
expressing the optimized pCAGa-optZGP expression cassette
was inserted into pShuttle using the restriction enzymes SpeI and
NheI and then cloned directly into the E1 region of human
adenovirus serotype 5 (BD Adeno-X expression system I, BD
Biosciences, Palo Alto, CA). The CMV driven wild-type sequence
of ZGP in the same adenovirus vector was used for comparison.
The authenticity of each vector was confirmed by sequencing and
the recombinant virus was rescued by transfecting the linearized
DNA into HEK 293 cells maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 1% penicillin, 1%
streptomycin, 1% L-glutamate, 1% sodium pyruvate, and 10%
fetal bovine serum. Large-scale infections (5610
8 cells) were
initiated from positive transfectants and purified by cesium
chloride as previously described [10]. Genome structures of
vectors were analyzed by restriction digestions of viral DNA and
compared with those of the molecular clones as previously
described [10]. Particle number and infectivity of vectors were
determined by standard optical density and immunodetection of
the hexon protein, respectively, following infection of HEK 293
cells with limiting dilutions of each vector preparation according to
the recommendations by the manufacturer (Adeno-X rapid titer
kit, Clontech, Mountain View, CA). Several Ad-CAGoptZGP and
Ad-CMVZGP preparations were generated and quantified for
both infectious particle and total particle number. Preparations
with a ratio below 1:200 infectious to total particle were used in
this study.
Expression of Ebola ZGP and optimized ZGP
HEK 293 cells were cultured in 6-well plates to approximately
80% confluence. The cells were infected with recombinant
adenoviral vectors Ad-CMVZGP or Ad-CAGoptZGP at a
M.O.I. of 5. The M.O.I. used for Ad-CMVZGP or Ad-
CAGoptZGP on HEK 293 cells was based total infectious
particles per ml as determined by immunocytochemistry against
the hexon protein (Adeno-X rapid titration kit, Clonetech,
Mountain View, CA). Preparations of Ad-CAGoptZGP or Ad-
CMVZGP used for expression analysis had a non-infectious to
infectious ratio of 73:1 or 19:1 respectively. The analysis was
repeated with a preparation of Ad-CAGoptZGP with non-
infectious to infectious ratio of 90:1 or Ad-CMVZGP with ratio
of 128:1 (not shown). At 24 hours, 48 hours, and 72 hours after
infection cell supernatants were removed from the tissue culture
well and 50 mLo f2 6 radioimmunoprecipitation (RIPA) buffer
(10 mL Triton X-100; 10 g lauryl sulfate; 5 mL 10% SDS; 30 mL
5 M NaCl; 20 mL 1 M Tris pH 7.7; 20 mL 0.5 M EDTA
pH 8.0) was added per 1 cm
2 surface area of tissue culture well.
Cell lysates were then collected, normalized by total protein
content and analyzed under reducing conditions with 56SDS-gel
loading buffer (50 mM Tris-HCl pH 6.8; 100 mM dithiothreitol;
2% (w/v) electrophoresis grade SDS; 0.1% bromophenol blue;
10% (v/v) glycerol on a 10% SDS-PAGE. Following electropho-
resis, proteins were transferred by electroblotting to a PVDF
membrane (Bio-Rad) and revealed with a mouse immune serum to
Ebola ZGP at a 1:1500 dilution as the primary antibody followed
by a horseradish peroxidase-conjugated goat anti-mouse second-
ary antibody diluted 1:7500. Immunodetection (Amersham ECL
system, Piscataway, NJ) was performed according to the
manufacturer. To determine band density proteins were trans-
ferred by electroblotting to Immobilon PVDF membrane (Milli-
pore). The membrane was blocked overnight in 100% Sea-Block
(Fisher) and then washed with PBS-Tween (0.01%). A mouse anti
Ebola-GP monoclonal antibody was used as the primary antibody
with a 1:1500 dilution and incubated for one hour. Antibody
against b-actin was used as a control at a dilution of 1:7500. The
membrane was then washed with PBS-Tween (0.01%) followed by
the addition of Cy5 secondary antibody (Cedarlane) at a dilution
of 1:100 for one hour. Scanning was accomplished using the
Typhoon 9410 and quantification using ImageQuant TL v2002.1.
Animal models, vaccination and challenge
B10.BR mice ((MHC H-2
K), The Jackson Laboratory, ME), a
strain in which a dominant CD8 epitope for ZGP has been
identified [27], were used to evaluate protection as well as B and T
cell immune responses against ZGP. The T cell response was
analyzed by evaluating the frequency of CD8+ T cells positive for
IFN-c production or cell division upon peptide stimulation by
FACS as previously described [10]. Groups of 8 to 11 B10.BR
mice were immunized with adenovirus vectors at a dose ranging
from 1610
4 to 1610
7 IFU per animal 28 days before challenge.
Mice were also vaccinated with Ad-CAGoptZGP at 5610
7 IFU/
mouse 30 minutes post-challenge. All protective and post-
exposure vaccines used in this study were derived from one of
two preparations of either Ad-CAGoptZGP or Ad-CMVZGP.
Preparations of Ad-CAGoptZGP had non-infectious to infectious
ratio of 73:1 and 90:1. Ad-CMVZGP preparations had ratio of
19:1 and 128:1. Vaccination was performed intramuscularly (I.M.)
with 50 ml of recombinant adenoviral vector diluted in PBS in
each posterior hind limb. Mice were challenged by intraperitoneal
injection with 10006LD50 in 200 ml of mouse-adapted ZEBOV
[17]. After challenge, the animals were weighed every day for 12
to 16 days and monitored for clinical signs using an approved
scoring sheet. All procedures and the scoring sheet were approved
by the Institutional Animal Care Committee at the National
Microbiology Laboratory (NML) of the Public Health Agency of
Canada (PHAC) according to the guidelines of the Canadian
Council on Animal Care. All infectious work was performed in the
‘Biosafety Level 4’ (BSL4) facility at NML, PHAC.
Neutralization assay
Sera collected from immunized mice were inactivated at 56uC
for 45 minutes and serial dilutions of each sample (1:10, 1:20,
1:40, etc, in 50 ml of DMEM) was mixed with equal volume of
ZEBOV expressing the EGFP reporter gene (ZEBOV-EGFP) [12]
(100 transducing units/well, according to EGFP expression) and
incubated at 37uC for 90 minutes. The mixture was then
transferred onto subconfluent VeroE6 cells in 96-well flat-
bottomed plates and incubated for 5–10 minutes at room
temperature. Control wells were infected with equal amounts of
ZEBOV-EGFP without addition of serum or with non-immune
serum. 100 ml of DMEM supplemented with 20% FBS was then
added to each well and plates were incubated at 37uCi n5 %C O 2
for 48 hours. Cells were subsequently fixed with 10% buffered
formalin for 24 hours and examined under a fluorescent
microscope. The total number of EGFP positive cells were
counted in each well and sample dilutions which showed .50%
reduction in the number of green cells compared to controls
scored positive for neutralizing antibody. All infectious in vitro work
was performed in the BSL4 laboratory of NML, PHAC.
Frequency of IFN-c, TNF-a and IL-2 positive CD8+ cells
Splenocytes or mononuclear cells were isolated by grinding
spleen tissues in L-15 medium and purifying cells through filtration
followed by 3 washes with PBS and resuspension in RPMI 1640.
Isolated splenocytes were pooled from 4 B10.BR mice per
experimental group 6 and 8 days post-immunization and added
to microwells along with the TELRTFSI [28] peptide which
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of the H-2
k haplotype (B10.BR). Control cells were incubated
either without peptide or with the nonspecific stimulator, SEB
(200 ng/ml). For the evaluation of IFN-c, TNF-a or IL-2 positive
CD8+ T cells, splenocytes (1610
6/sample) were cultured for
5 hours at 37uC in 96-well round bottom microtiter plate wells in
DMEM supplemented with 10% FBS, 10
26 M 2-ME and
GolgiStop (BD PharMingen, San Diego, CA) at 1 ml/ml as
described previously [10]. Briefly, stimulated cells were stained
with a FITC-anti mouse CD8a (BD PharMingen) at 1:300 dilution
followed by a PE-anti mouse IFN-c antibody (BD PharMingen)
diluted 1:150 or PECY7-anti mouse TNF-a antibody (BD
PharMingen) diluted at 1:100 or APC-anti mouse IL-2 antibody
(BD PharMingen) diluted at 1:100. Stained cells were run through
a LSRII flow cytometer, acquiring at least 300,000 events per
sample. Final data analyses were performed using the software
Flowjo (Ashland, OR). A response was considered positive when
the frequency from stimulated samples was over twice that of non-
stimulated cells or those stimulated with unrelated peptides.
Samples for the ELISPOT assay and the evaluation of IFN-c
positive CD8+ T cells were tested in duplicate and each
experiment repeated twice.
Statistical analysis
Data were analyzed for statistical difference by performing one-
way analysis of variance (ANOVA, Tukey-Kramer multiple
comparisons test) or repeated measure ANOVA when appropri-
ate. The differences in the mean or raw values among treatment
groups were considered significant when p,0.05.
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